TheTechno Optimist.

HYDROS Robotic System (Aquablation)PROCEPT BioRobotics—PROCEPT completes 280-patient WATER IV enrollment comparing Aquablation with prostate removal, wins IDE for second cancer trialHYDROS Robotic System (Aquablation)PROCEPT BioRobotics—PROCEPT Q2 2026: revenue up 19% to $94.5M, record HYDROS placements, 816 US systems installed
HYDROS Robotic System (Aquablation)
Courtesy of PROCEPT BioRobotics · Press kit, editorial use (opens procept-biorobotics.com)

HYDROS Robotic System (Aquablation)

by PROCEPT BioRoboticsUS

Give men with an enlarged prostate a durable fix with fewer sexual and urinary side effects than heat-based surgery, for any prostate size, and later extend it to prostate cancer.

ScalingStage 5 of 5

816 US systems at June 2026 after record HYDROS placements; cancer trial results due spring 2027.

Updated 4 Aug 2026Checked 11 Oct0 updates this week

Milestones

Next · WATER IV primary results at AUA meeting
  1. AquaBeam granted FDA De Novo for BPH21 Dec 2017Complete.
  2. Nasdaq IPO raises $164M14 Sep 2021Complete.
  3. Approval in JapanFeb 2022Complete.
  4. HYDROS cleared by FDA (510(k))Aug 2024Complete.
  5. WATER IV cancer trial (vs prostatectomy) fully enrolled28 May 2026Complete.
  6. WATER IV primary results at AUA meetingTarget 2027Current milestone.

Most important updates

Upcoming

  1. 2027WATER IV primary results at AUA meeting (next)
Primer